Evidence map›Paper›PMID 36755215›Full record

ArticleBMC nephrology2023

Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: a Chinese case series.

Lin Liu, Haitao Lu, Guming Zou, Haifeng Wang, Jing Li, Yue Yang, Jian Zhang, Xueling Wang, Wenge Li, Li Zhuo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Lin LiuDepartment of Nephrology, China-Japan Friendship Hospital, No.2, East Yinghua Street, Beijing, 100029, People's Republic of China.ORCID 0000-0001-9690-1302
Haitao LuDepartment of Nephrology, China-Japan Friendship Hospital, No.2, East Yinghua Street, Beijing, 100029, People's Republic of China.
Guming ZouDepartment of Nephrology, China-Japan Friendship Hospital, No.2, East Yinghua Street, Beijing, 100029, People's Republic of China.
Haifeng WangDepartment of Nephrology, China-Japan Friendship Hospital, No.2, East Yinghua Street, Beijing, 100029, People's Republic of China.
Jing LiDepartment of Nephrology, China-Japan Friendship Hospital, No.2, East Yinghua Street, Beijing, 100029, People's Republic of China.
Yue YangDepartment of Nephrology, China-Japan Friendship Hospital, No.2, East Yinghua Street, Beijing, 100029, People's Republic of China.
Jian ZhangDepartment of Nephrology, China-Japan Friendship Hospital, No.2, East Yinghua Street, Beijing, 100029, People's Republic of China.
Xueling WangDepartment of Nephrology, China-Japan Friendship Hospital, No.2, East Yinghua Street, Beijing, 100029, People's Republic of China.
Wenge LiDepartment of Nephrology, China-Japan Friendship Hospital, No.2, East Yinghua Street, Beijing, 100029, People's Republic of China.
Li ZhuoDepartment of Nephrology, China-Japan Friendship Hospital, No.2, East Yinghua Street, Beijing, 100029, People's Republic of China. belindazhl@aliyun.com.
China-Japan Friendship Hospital · CN

Funding

National Key Clinical Specialty Capacity Building Project of China 2019-QTL-013the National Natural Science Foundation of China 81600547the National Natural Science Foundation of China 81870495
6 · The paper itself

Abstract

backgroundRituximab (RTX) is a standard therapy for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, the most frequently used dose may lead to severe adverse effects (SAEs). We explored the efficacy and safety of low-dose RTX in Chinese patients with AAV.

methodsA total of 22 Chinese patients diagnosed with AAV with renal involvement, including 8 treated with low-dose RTX (400 mg of RTX total over 4 weeks) and 14 treated with cyclophosphamide (CYC), were evaluated. The baseline clinical and pathological data and laboratory parameters during follow-up at months 1, 3, 6, and 12 were collected retrospectively.

resultsThe baseline data showed no significant differences between the two groups. The median peripheral CD19

conclusionsThis is the first report that low-dose RTX could be effective for the treatment of Chinese patients with AAV with renal involvement.

Indexed as

Antibodies, Antineutrophil CytoplasmicAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisRituximabCyclophosphamideEast Asian PeopleHumansInduction ChemotherapyRemission InductionRetrospective StudiesTreatment OutcomeAntibodies, Antineutrophil CytoplasmicCyclophosphamideRituximabAntineutrophil cytoplasmic antibody-associated vasculitisLow-doseRenal injuryRituximab

Identifiers

PMID36755215
PMCPMC9906883
OpenAlexW4319600451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.